Dr. Li Jie
Managing Director @ Redhill Capital
Dr. Li Jie is a angel investor at Redhill Capital focused on Biopharma and Health Care. Dr. Li Jie is Managing Director of Danlu Capital.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Dr. Li Jie invests in
Stages Dr. Li Jie invests in
Countries Dr. Li Jie invests in
Investment Focus
Industry
- Biopharma 2 (40%)
- Health Care 2 (40%)
- Pharmaceutical 2 (40%)
- Biotechnology 1 (20%)
- Information Technology 1 (20%)
Stage
- Angel 2 (40%)
- Seed 1 (20%)
- Series A 1 (20%)
- Venture - Series Unknown 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inflamax Pharmaceuticals
|
Inflamax Pharmaceuticals is a biomedical technology company that specializes in the innovation and development of immune-inflammatory drugs. | Angel / Oct 20, 2023 | |
Metanovas Biotech
|
Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M / Angel / Mar 31, 2022 | |
|
Metanovas Biotech
|
Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M / Seed / Mar 30, 2022 | |
Vibrant
|
Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China. | $15.7M / Venture - Series Unknown / Jan 13, 2022 | |
Xinji Pharmaceuticals
|
Xinji Pharmaceuticals is mainly engaged in the R&D of new drug preparations and drug release systems. The company is especially involved in the application and promotion of drug-controlled release, sustained release, and targeted drug release technologies in the industrialization of biomedicine. | $15.7M / Series A / Dec 07, 2021 |
Co-Investors
About Redhill Capital
Redhill Capital is a venture capital firm specializing in early stage investment. It primary invests in medical industry.
Redhill Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Frank Su
Founding Partner
|
|||
Cherry Lu
Founding and Managing Partner
|
|||
|
Dr. Li Jie
Managing Director
|
|||
Lu Qinchao
Redhill Capital is a venture capital firm focusing on the medical industry.
|
|||
1 more contact available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dr. Li Jie invest in?
Dr. Li Jie invests primarily in Biopharma, Health Care and Pharmaceutical startups, most often at Angel and Seed stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dr. Li Jie last invest?
The most recent investment recorded for Dr. Li Jie closed in Oct 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
